Dr Mark Yarchoan speaks to ecancer in an online interview for the virtual AACR 2020 meeting.

He discusses the NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study into atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers.

Dr Yarchoan details some background to biliary tract cancers before explaining the design of the trial and what results were seen.

He concluded by stating that the combination was promising, as it met its primary endpoint for progression free survival, however the low response rates highlight the challenge of immunotherapy in this tumour type.